10-K/A: Wave Life Sciences Files Amendment No. 1 to Form 10-K/A: Updates on Executive Compensation and Corporate Governance

Wave Life Sciences Ltd. files an amendment to its 2024 annual report, primarily to include previously omitted information regarding executive compensation, corporate governance, and updated certifications.

Summary

• Wave Life Sciences Ltd. has filed Amendment No. 1 to its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2024.
• The amendment includes information required by Part III of the Annual Report on Form 10-K, which was intentionally omitted from the original filing.
• It also updates the exhibit list in Item 15 of Part IV and includes new certifications by the principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002.
• The original 10-K speaks as of the dates described within it, and disclosures have not been updated to reflect events occurring after those dates.
• The aggregate market value of the registrant's voting and non-voting ordinary shares held by non-affiliates was $488,707,919 as of June 28, 2024.
• As of March 31, 2025, the number of outstanding ordinary shares was 154,089,713.
• The amendment details the composition and activities of the Board of Directors and its committees, including the Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Research and Development Committee.
• Executive compensation information is provided, including base salaries, annual performance-based cash incentives, and long-term equity incentive awards for named executive officers (NEOs).
• The company's executive compensation program aims to attract, retain, and motivate superior executive talent, reward achievement of performance goals, and align executive interests with those of shareholders.
• In 2024, the company achieved 125% of its corporate goals, leading to incentive payouts for NEOs.
• Long-term incentive compensation in 2025 consists of a mix of share options and time-based restricted share units (RSUs).
• The amendment also covers director compensation, related party transactions, and director independence.
• The company has a related person transaction policy requiring Audit Committee approval for transactions exceeding $120,000.
• The company's independent registered public accounting firm is KPMG LLP, and audit fees for 2024 totaled $1,739,629.
• The document includes certifications from the Principal Executive Officer and Principal Financial Officer regarding the accuracy and completeness of the report.

Sentiment

Score: 7

Explanation: The document is primarily factual and informative, with a neutral tone. The inclusion of risk factors tempers the overall sentiment, but the company's achievements and compensation practices suggest a positive outlook.

Positives

• The company has a well-defined executive compensation program aimed at aligning executive interests with shareholder value.
• The Board of Directors includes several independent members, ensuring objective decision-making.
• The company has a related person transaction policy to prevent conflicts of interest.
• The company achieved 125% of its 2024 corporate goals.
• Long-term incentive compensation for 2025 includes both share options and restricted share units (RSUs).

Negatives

• The amendment was required to include information intentionally omitted from the original filing, suggesting a potential oversight in the initial reporting process.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.
• These risks include the ability to fund future operations, the success of research and development activities, regulatory approvals, competition, and the impact of global health epidemics and economic uncertainty.

Future Outlook

The amendment contains forward-looking statements regarding future events and financial performance, which are subject to risks and uncertainties. The company anticipates that subsequent events and developments may cause their views to change and undertakes no obligation to update these statements publicly.

Management Comments

• Our Compensation Committee will continue to monitor and evaluate our executive compensation program going forward in light of our shareholders views and our transforming business needs.
• Our Compensation Committee expects to continue to consider the outcome of our say-on-pay votes and our shareholders views when making future compensation decisions for the NEOs.

Industry Context

The document provides insights into Wave Life Sciences' executive compensation practices, board composition, and corporate governance policies, which are essential for investors to assess the company's management and oversight. The company operates in the competitive biopharmaceutical industry, and its ability to attract and retain key personnel is crucial for its success.

Comparison to Industry Standards

• The document mentions a peer group of publicly traded companies in the biopharmaceutical industry used for benchmarking executive compensation, including Alector, Inc., Intellia Therapeutics, Inc., Arcturus Therapeutics Holdings, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Prime Medicine, Inc., Avidity Biosciences, Inc., PTC Therapeutics, Inc., Beam Therapeutics, Inc., Sangamo Therapeutics, Denali Therapeutics, Inc., Stoke Therapeutics, Inc., Dyne Therapeutics, Inc., Verve Therapeutics, Inc., and Editas Medicine, Inc..
• The company's compensation practices are evaluated against these peers to ensure competitiveness in attracting and retaining executive talent.
• The document also references compliance with SEC and Nasdaq rules regarding clawback policies and director independence, aligning with industry standards for corporate governance.

Related Party Transactions

• Gregory L. Verdine, Ph.D., a member of our Board, entered into a consulting agreement with Wave Life Sciences USA, Inc.
• On December 13, 2022, Wave Life Sciences USA, Inc. and Wave Life Sciences UK Limited, two of our direct, wholly-owned subsidiaries entered into a Collaboration and License Agreement (the GSK Collaboration Agreement) with GlaxoSmithKline Intellectual Property (No. 3) (GSK), which became effective on January 27, 2023.
• As a part of the September 2024 Offering, GSK plc, a 5% or greater holder of our ordinary shares, purchased 2,791,930 ordinary shares at the public offering price of $8.00 per share.
• In April 2023, we engaged SNBL to provide approximately $2.8 million in certain non-human primates (NHPs) contract research services to us.

Stakeholder Impact

• Shareholders: The document provides information relevant to assessing the company's management and financial performance.
• Employees: The document details executive compensation and benefit plans.
• Customers: The document highlights the company's research and development activities, which could lead to new products and services.
• Suppliers: The document mentions related party transactions, including contract research services provided by SNBL.
• Creditors: The document provides information about the company's financial position and future outlook.

Next Steps

• The company will continue to monitor and evaluate its executive compensation program.
• The company will hold its 2026 Annual General Meeting of Shareholders.

Key Dates

Keywords

executive compensation, corporate governance, annual report, amendment, directors, officers, shareholders, financial statements, risk factors, Wave Life Sciences